In a significant advancement for lung cancer treatment, Pfizer Inc. has unveiled new data showing that the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) markedly improves long-term survival rates in patients suffering from advanced non-small cell lung cancer (NSCLC). The updated results from the Phase 2 PHAROS trial indicate that treatment-naïve patients with the BRAF V600E mutation achieved a median overall survival (OS) of 47.6 months following a median follow-up period of 52.3 months. In contrast, previously treated patients experienced a median OS of 22.7 months.
These findings, which will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, offer a new benchmark in the treatment landscape for this patient demographic, which previously faced poor outcomes with conventional chemotherapy. The OS rates after four years stood at 49% for treatment-naïve patients and 31% for those who had already undergone treatment.
Expert Insights on the Trial Findings
According to Dr. Melissa Johnson, Director of Lung Cancer Research at Sarah Cannon Research Institute and an investigator in the PHAROS trial, the results represent a significant milestone for patients with the BRAF V600E mutation. Dr. Johnson emphasized that these results not only set a new standard for survival in this specific group but also instill hope for improved treatment outcomes. She noted that the survival outcomes observed are unparalleled for patients presenting with treatment-naïve metastatic NSCLC.
Lung cancer remains the leading cause of cancer-related mortality globally, with NSCLC accounting for approximately 80-85% of lung cancer cases. The occurrence of BRAF V600E mutations is estimated at around 2% among NSCLC patients. The advent of targeted therapies like BRAFTOVI and MEKTOVI marks a significant shift in treatment options available for these patients.
Safety Profile and Regulatory Approvals
The safety profile of the BRAFTOVI and MEKTOVI combination has been consistent with previous studies, with common treatment-related side effects including nausea, diarrhea, and fatigue. More serious adverse events, while noted, were manageable within the clinical framework of the trial.
The combination therapy was approved by the U.S. Food and Drug Administration (FDA) in October 2023 and subsequently by the European Commission in August 2024, based on the promising results from the initial phases of the PHAROS trial. The overall response rate (ORR) for treatment-naïve patients was found to be 75%, indicating strong efficacy.
As part of its ongoing commitment to enhance understanding of its research findings, Pfizer has developed plain language summaries aimed at making clinical trial results more accessible to non-scientists. Interested parties can access these summaries through Pfizer’s website.
In summary, the pioneering efforts of Pfizer in the development of targeted therapies for lung cancer signify a hopeful future for patients battling this challenging disease, with the BRAFTOVI and MEKTOVI combination representing a critical advancement in treatment possibilities.
Related
